- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03624972
Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study
15. března 2021 aktualizováno: Fox Chase Cancer Center
Enhancing Patient-Provider Communication About Sexual Concerns in Breast Cancer: Patient Intervention Study
The goal of this study is to evaluate an educational video intervention (called Starting the Conversation) aimed to enhance breast cancer patients' beliefs about and communication with respect to sexual concerns.
In the current study, 128 breast cancer outpatients will be randomized to either participate in the video intervention and to receive a resource guide addressing sexual and menopausal health or to receive the resource guide alone.
Patients will be asked to participate in the video and/or read through the resource guide prior to their clinic visit with their breast cancer provider.
The investigators will examine effects of the interventions on patients' beliefs about communication about sexual health and on patients' communication about sexual health during clinic visits with their providers.
Secondarily, the investigators will examine effects of the interventions on sexual outcomes and other health outcomes, including psychological well-being and health-related QOL.
Přehled studie
Postavení
Dokončeno
Podmínky
Typ studie
Intervenční
Zápis (Aktuální)
153
Fáze
- Nelze použít
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19111
- Fox Chase Cancer Center
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
21 let a starší (Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ne
Pohlaví způsobilá ke studiu
Ženský
Popis
Inclusion Criteria:
- Receiving any treatment for breast cancer or have completed acute treatment for breast cancer < 10 years ago
- Attending clinic visits in the course of follow-up care (i.e., not an initial consult visit)
- Willing to have clinic visit audio recorded
Exclusion Criteria:
- Unable to speak English
- Eastern Cooperative Oncology Group (ECOG) Performance score > 2 OR too ill to participate as judged by physician, self-report, or observation of the research team member
- Overt cognitive dysfunction or psychiatric disturbance or severe mental illness (e.g., dementia, suicidal behavior, or psychosis), as observed or judged by the researcher or referring source.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Podpůrná péče
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Aktivní komparátor: Resources Only
Patients will receive a list of resources on sexual and menopausal health in breast cancer.
They will be asked to review the resources before their next clinic visit.
|
Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal & sexual health clinic.
|
Experimentální: Resources + Video
Patients will receive a list of web resources on sexual and menopausal health in breast cancer.
In addition to the resources, patients will be asked to view an online video called "Starting the Conversation" and to complete an accompanying workbook.
Patients in this arm will be asked to review the resource list, watch the Starting the Conversation video, and complete the workbook before their next clinic visit.
|
Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal & sexual health clinic.
The Starting the Conversation program is designed to increase self-efficacy and outcome expectancies for communicating with providers about sexual health and related issues, reduce barriers to communication, and provide basic training in skills for communicating with providers about these topics, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback.
|
Žádný zásah: Clinician Arm
Clinicians were consented in order to have their clinic visits audio recorded.
No outcomes data were collected from clinician participants.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Self-Reported Self-Efficacy for Communicating About Sexual Health Issues
Časové okno: 2 weeks
|
Two items assessed patients' self-efficacy (confidence) for communicating with their breast cancer clinician about sexual health concerns in terms of either talking (item 1) or asking (item 2) about sexual health.
Response options used an 11-point scale (0=not at all confident/not at all to 10=extremely confident/very much).
Mean scores across the two items were used, ranging from 0-10.
Higher scores indicate higher self-efficacy.
|
2 weeks
|
Self-Reported Self-Efficacy for Communicating About Sexual Health Issues
Časové okno: 2 months
|
Two items assessed patients' self-efficacy (confidence) for communicating with their breast cancer clinician about sexual health concerns in terms of either talking (item 1) or asking (item 2) about sexual health.
Response options used an 11-point scale (0=not at all confident/not at all to 10=extremely confident/very much).
Mean scores across the two items were used, ranging from 0-10.
Higher scores indicate higher self-efficacy.
|
2 months
|
Self-Reported Outcome Expectancies for Sexual Health Communication
Časové okno: 2 weeks
|
Five items assessed the belief that discussing sexual health with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 weeks
|
Self-Reported Outcome Expectancies for Sexual Health Communication
Časové okno: 2 months
|
Five items assessed the belief that discussing sexual health with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 months
|
Number of Patients Who Asked at Least One Question About Sexual Health at Their Clinic Visit
Časové okno: 2 weeks
|
As coded from clinic visit audio, the number of patients who ask at least one question about sexual health.
|
2 weeks
|
Number of Patients Who Initiate Conversation About Sexual Health in Their Clinic Visit
Časové okno: 2 weeks
|
As coded from clinic visit audio, the number of patients who raise the topic of sexual health during their encounter (out of encounters where a sexual health discussion occurred).
|
2 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Recruitment Rates (Feasibility)
Časové okno: baseline
|
Recruitment rates, as measured by percentage of patients enrolled (i.e., baselined) out of eligible patients approached for the study.
|
baseline
|
Retention Rates (Feasibility)
Časové okno: 2 weeks
|
Retention rates, as measured by percentage of patients who remain on study for 2-week follow-up assessment.
|
2 weeks
|
Retention Rates (Feasibility)
Časové okno: 2 months
|
Retention rates, as measured by percentage of patients who remain on study for 2-month follow-up assessment.
|
2 months
|
Intervention Acceptability
Časové okno: 2 weeks
|
Acceptability of intervention, as measured through the item "Overall, how satisfied were you with this program?".
Responses options include Very Satisfied, Satisfied, Dissatisfied, and Very Dissatisfied.
Responses of "satisfied" or "very satisfied" indicate acceptability.
Number of patients reporting acceptability and number of patients not reporting acceptability are presented.
|
2 weeks
|
Sexual Activity
Časové okno: 2 months
|
Sexual activity was measured by a single item asking (yes/no) whether the participant had any kind of sexual activity in the past 30 days.
|
2 months
|
Sexual Function
Časové okno: 2 months
|
Sexual function was assessed using the Lubrication, Vaginal Discomfort, Satisfaction, and Interest domain scores from the Patient-Reported Outcomes Measurement Information System Sexual Function and Satisfaction scale (PROMIS SexFS) Brief Profile Version 2.0.
Scores are converted to a T-score metric where a score of 50 equates to the mean of the U.S. population of sexually active adults (SD=10).
Higher scores for all domains except Vaginal Discomfort signify better function.
|
2 months
|
General Self-Efficacy for Communication With Provider
Časové okno: 2 months
|
Patients' self-efficacy for communicating with provider generally, as measured through the Perceived Efficacy in Patient-Physician Interactions Scale (PEPPI-5).
The PEPPI-5 is a five-item scale that measures patient confidence in communicating with providers.
Response options are on a scale from 1 (Not at All Confident) to 5 (Very Confident) and are summed for a total self-efficacy score (Range: 5-25).
Higher scores indicate higher self-efficacy.
|
2 months
|
Barriers to Communicating About Sexual Health
Časové okno: 2 months
|
Patient barriers to communication about sexual health, as measured through a 13-item scale.
Scale items cover potential reasons a patient might not want to discuss sexual health concerns with her provider (e.g., "I might become embarrassed").
Items are scored on a 1-5 scale where 1=Strongly Disagree and 5=Strongly Disagree.
A total barrier score will be taken from this scale (Range: 13-65).
Higher scores indicate more perceived barriers to communication.
|
2 months
|
Self-Reported Anxiety
Časové okno: 2 months
|
Patients self-reported anxiety, as measured through anxiety subscale of the Hospital Anxiety & Depression Scale (HADS).
The anxiety subscale consists of 7 items that are scored from 0 to 3. Summed scores range from 0 to 21, with higher scores indicating higher levels of anxiety.
|
2 months
|
Self-Reported Depression
Časové okno: 2 months
|
Patients self-reported depression, as measured through depression subscale of the Hospital Anxiety & Depression Scale (HADS).
The depression subscale consists of 7 items that are scored from 0 to 3. Summed scores range from 0 to 21, with higher scores indicating higher levels of depression.
|
2 months
|
Self-Reported Quality of Life
Časové okno: 2 months
|
Quality of life, as measured through the Abbreviated Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) total score.
The FACT-B contains 23 items about physical, functional, and emotional well-being in the context of breast cancer.
Scale items are scored from 0 to 4. Summed scores run from 0 to 92, with higher scores indicating higher quality of life.
|
2 months
|
Self-Reported Self-Efficacy for Communicating About About Treatment Side Effects
Časové okno: 2 weeks
|
Patients' self-reported self-efficacy for communication about treatment side effects with their breast cancer provider.
The items about treatment side effects consist of 2 items within a larger 6-item scale which ask the patient how confident she is in talking to her provider about treatment side effects and asking her provider about treatment side effects.
Response options range from 0 (not at all confident) to 10 (extremely confident).
Mean scores will be reported.
|
2 weeks
|
Self-Reported Self-Efficacy for Communicating About About Treatment Side Effects
Časové okno: 2 months
|
Patients' self-reported self-efficacy for communication about treatment side effects with their breast cancer provider.
The items about treatment side effects consist of 2 items within a larger 6-item scale which ask the patient how confident she is in talking to her provider about treatment side effects and asking her provider about treatment side effects.
Response options range from 0 (not at all confident) to 10 (extremely confident).
Mean scores will be reported.
|
2 months
|
Self-Reported Self-Efficacy for Communicating About About Menopausal Health
Časové okno: 2 weeks
|
Patients' self-reported self-efficacy for communication about menopausal health with their breast cancer provider.
The items about menopausal health consist of 2 items within a larger 6-item scale which ask the patient how confident she is in talking to her provider about menopausal health and asking her provider about menopausal health.
Response options range from 0 (not at all confident) to 10 (extremely confident).
Mean scores will be reported.
|
2 weeks
|
Self-Reported Self-Efficacy for Communicating About About Menopausal Health
Časové okno: 2 months
|
Patients' self-reported self-efficacy for communication about menopausal health with their breast cancer provider.
The items about menopausal health consist of 2 items within a larger 6-item scale which ask the patient how confident she is in talking to her provider about menopausal health and asking her provider about menopausal health.
Response options range from 0 (not at all confident) to 10 (extremely confident).
Mean scores will be reported.
|
2 months
|
Self-Reported Outcome Expectancies for Communication About Treatment Side Effects
Časové okno: 2 weeks
|
Five items assessed the belief that discussing treatment side effects with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 weeks
|
Self-Reported Outcome Expectancies for Communication About Treatment Side Effects
Časové okno: 2 months
|
Five items assessed the belief that discussing treatment side effects with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 months
|
Self-Reported Outcome Expectancies for Communication About Menopausal Health
Časové okno: 2 weeks
|
Five items assessed the belief that discussing menopausal health with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 weeks
|
Self-Reported Outcome Expectancies for Communication About Menopausal Health
Časové okno: 2 months
|
Five items assessed the belief that discussing menopausal health with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 months
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Spolupracovníci
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia (Aktuální)
27. května 2018
Primární dokončení (Aktuální)
31. prosince 2019
Dokončení studie (Aktuální)
31. prosince 2019
Termíny zápisu do studia
První předloženo
20. července 2018
První předloženo, které splnilo kritéria kontroly kvality
7. srpna 2018
První zveřejněno (Aktuální)
10. srpna 2018
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
16. března 2021
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
15. března 2021
Naposledy ověřeno
1. března 2021
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 14-833-02
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
NE
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Ne
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ne
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Rakovina prsu žena
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital a další spolupracovníciDokončenoPrůvodce klinickou aplikací Conebeam Breast CTČína
-
Gangnam Severance HospitalNáborHER2 Enriched Subtype Cancer Breast, Herzuma, PAM50 StudyKorejská republika
-
BioNTech SESeventh Framework ProgrammeDokončenoRakovina prsu (Triple Negative Breast Cancer (TNBC))Švédsko, Německo
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Zatím nenabírámeAnatomický karcinom prsu stadia II AJCC v8 | Anatomický karcinom prsu stadia III AJCC v8 | Rané stadium karcinomu prsu | Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8Spojené státy
-
Emory UniversityNational Cancer Institute (NCI)StaženoPrognostický karcinom prsu stadia IV AJCC v8 | Metastatický maligní novotvar v mozku | Metastatický karcinom prsu | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktivní, ne náborAnatomický karcinom prsu stadia IV AJCC v8 | Prognostický karcinom prsu stadia IV AJCC v8 | Metastatický maligní novotvar v kosti | Metastatický maligní novotvar v lymfatických uzlinách | Metastatický maligní novotvar v játrech | Metastatický karcinom prsu | Metastatický maligní novotvar v plicích | Metastatický... a další podmínkySpojené státy, Kanada, Saudská arábie, Korejská republika
Klinické studie na Sexual and Menopausal Health Resources
-
University of CalgaryNáborDeprese | Závislost | Domácí násilí | ChudobaKanada
-
Ohio State University Comprehensive Cancer CenterDokončenoSexuální dysfunkce | Rakovina prostaty | Mužská erektilní poruchaSpojené státy
-
Brigham and Women's HospitalNational Aeronautics and Space Administration (NASA)Dokončeno
-
Assuta Hospital SystemsDokončeno
-
Public Health Foundation Enterprises, Inc.NáborPoužití látky | Problém duševního zdravíSpojené státy
-
Massachusetts Institute of TechnologyMcGill University; United States Agency for International Development (USAID); Kehea... a další spolupracovníciDokončenoTuberkulóza | Adherence, léky | Tuberkulóza odolná vůči lékům | Přilnavost, pacienteKeňa
-
University of BirminghamNational Institute for Health Research, United KingdomNeznámýRevmatoidní artritida | Zánětlivá onemocnění střev | Chronické onemocnění jaterSpojené království
-
Sinai Health SystemNáborDiabetes mellitus, typ 2 | Diabetes Mellitus | Diabetes | Diabetes mellitus, typ 1Spojené státy
-
CHU de Quebec-Universite LavalTerSera Therapeutics LLCNáborRakovina prostaty | Radioterapie vedlejší účinek | Uzel; ProstataKanada
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)NáborVzdělávání proti rakovině | Španělské jazykové vzdělávání proti rakoviněSpojené státy, Portoriko